Screening for diabetes and prediabetes should be cost-saving in patients at high risk

Diabetes Care

Volumn 36, Issue 7, 2013, Pages 1981-1987

  Chatterjee, Ranee ^a   Narayan, K M Venkat ^b,c   Lipscomb, Joseph ^b,d   Jackson, Sandra L ^e   Long, Qi ^b   Zhu, Ming ^b   Phillips, Lawrence S ^b,c,d  

^a DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b EMORY UNIVERSITY   (United States)

^c EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d ATLANTA VA MEDICAL CENTER   (United States)

^e EMORY UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCOSE; LIPID; METFORMIN;

ADULT; ARTICLE; BLOOD PRESSURE; BODY MASS; CONTROLLED STUDY; COST CONTROL; DIABETES MELLITUS; FALSE NEGATIVE RESULT; FEMALE; HEALTH CARE COST; HEALTH CARE SYSTEM; HEALTH ECONOMICS; HIGH RISK PATIENT; HUMAN; IMPAIRED GLUCOSE TOLERANCE; MAJOR CLINICAL STUDY; MALE; MEDICARE; ORAL GLUCOSE TOLERANCE TEST; RISK FACTOR; SCREENING TEST; SYSTOLIC BLOOD PRESSURE; WAIST CIRCUMFERENCE;

ADULT; AGED; BLOOD GLUCOSE; DIABETES MELLITUS; FEMALE; HUMANS; MALE; MASS SCREENING; MIDDLE AGED; PREDIABETIC STATE;

EID: 84886070337     PISSN: 01495992     EISSN: 19355548     Source Type: Journal    
DOI: 10.2337/dc12-1752     Document Type: Article

References (26)

1. American Diabetes Association. Standards of medical care in diabetes-2010. Diabetes Care 2010;33(Suppl. 1):S11-S61.
2. Kahn R, Alperin P, Eddy D, et al. Age at initiation and frequency of screening to detect type 2 diabetes: a cost-effectiveness analysis. Lancet 2010;375:1365-1374
3. Leiter LA, Barr A, Bélanger A, et al.; Diabetes Screening in Canada (DIASCAN) Study. Diabetes Screening in Canada (DIASCAN) Study: prevalence of undiagnosed diabetes and glucose intolerance in family physician offices. Diabetes Care 2001; 24:1038-1043
4. Chatterjee R, Narayan KM, Lipscomb J, Phillips LS. Screening adults for pre-diabetes and diabetes may be cost-saving. Diabetes Care 2010;33:1484-1490
5. Phillips LS, Ziemer DC, Kolm P, et al. Glucose challenge test screening for prediabetes and undiagnosed diabetes. Diabetologia 2009; 52:1798-1807
6. Sorkin JD, Muller DC, Fleg JL, Andres R. The relation of fasting and 2-h postchallenge plasma glucose concentrations to mortality: data from the Baltimore Longitudinal Study of Aging with a critical review of the literature. Diabetes Care 2005;28:2626-2632
7. Kanaya AM, Herrington D, Vittinghoff E, et al. Impaired fasting glucose and cardiovascular outcomes in postmenopausal women with coronary artery disease. Ann Intern Med 2005;142:813-820
8. Knowler WC, Barrett-Connor E, Fowler SE, et al.; Diabetes Prevention Program Research Group. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002;346:393-403
9. Hernan WH, Brandle M, Zhang P, et al.; Diabetes Prevention Program Research Group. Costs associated with the primary prevention of type 2 diabetes mellitus in the diabetes prevention program. Diabetes Care 2003;26:36-47
10. Trogdon JG, Hylands T. Nationally representative medical costs of diabetes by time since diagnosis. Diabetes Care 2008; 31:2307-2311
11. Nichols GA, Brown JB. Higher medical care costs accompany impaired fasting glucose. Diabetes Care 2005;28:2223-2229
12. Nichols GA, Bhakti A, Herman WH. Medical care costs one year after identification of hyperglycemia below the threshold for diabetes.Med Care 2008;46: 287-292
13. Diabetes Prevention Program Research Group. Within-trial cost-effectiveness of lifestyle intervention or metformin for the primary prevention of type 2 diabetes. Diabetes Care 2003;26:2518-2523
14. American Diabetes Association. Economic costs of diabetes in the U.S. In 2007. Diabetes Care 2008;31:596-615
15. Thompson SG, Barber JA. How should cost data in pragmatic randomised trials be analysed? BMJ 2000;320:1197-1200
16. Li R, Zhang P, Barker LE, Chowdhury FM, Zhang X. Cost-effectiveness of interventions to prevent and control diabetes mellitus: a systematic review. Diabetes Care 2010;33: 1872-1894
17. Hoerger TJ, Harris R, Hicks KA, Donahue K, Sorensen S, Engelgau M. Screening for type 2 diabetes mellitus: a cost-effectiveness analysis. Ann Intern Med 2004;140: 689-699
18. Hoerger TJ, Hicks KA, Sorensen SW, et al. Cost-effectiveness of screening for pre-diabetes among overweight and obese U.S. adults. Diabetes Care 2007;30:2874-2879
19. Gillies CL, Lambert PC, Abrams KR, et al. Different strategies for screening and prevention of type 2 diabetes in adults: cost effectiveness analysis. BMJ 2008;336:1180-1185
20. Waugh N, Scotland G, McNamee P, et al. Screening for type 2 diabetes: literature review and economic modeling: Executive Summary. Health Technol Assess 2007. Availalble from http://eprints.whiterose.ac. uk/10716. Accessed June 2012
21. Cowie CC, Rust KF, Ford ES, et al. Full accounting of diabetes and pre-diabetes in the U.S. population in 1988-1994 and 2005-2006. Diabetes Care 2009;32:287-294
22. Zhang Y, Dall TM, Chen Y, et al. Medical cost associated with prediabetes. popul. Health Manage 2009;12:157-163
23. Zhang Y, Dall TM, Mann SE, et al. The economic costs of undiagnosed diabetes. Popul Health Manag 2009;12:95-101
24. Johansson P, Ostenson CG, Hilding AM, Andersson C, Rehnberg C, Tillgren P. A cost-effectiveness analysis of a communitybased diabetes prevention program in Sweden. Int J Technol Assess Health Care 2009;25:350-358
25. Smith KJ, Hsu HE, Roberts MS, et al. Cost effectiveness analysis of efforts to reduce risk of type 2 diabetes and cardiovascular disease in southwestern Pennsylvania, 2005-2007. Prev Chronic Dis 2010;7: A109
26. Eriksson MK, Hagberg L, Lindholm L, Malmgren-Olsson EB, Osterlind J, Eliasson M. Quality of life and cost-effectiveness of a 3-year trial of lifestyle intervention in primary health care. Arch Intern Med 2010; 170:1470-1479